Osbon Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.5K Buy
82
+1
+1% +$125 0.01% 283
2025
Q4
$9.93K Buy
+81
New +$9.29K 0.01% 234

Other funds holding XBI

Osbon Capital Management's XBI Position: Q1 2026 in Review

Osbon Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.2% in Q1 2026, buying an estimated $125 and bringing the position to 82 shares worth $10.5K. The position accounts for 0.01% of the portfolio, ranked #283.

Osbon Capital Management first reported a position in XBI in Q4 2025 and has held it in 2 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Osbon Capital Management held 82 shares of State Street SPDR S&P Biotech ETF worth $10.5K as of Q1 2026.
  • Osbon Capital Management bought 1 State Street SPDR S&P Biotech ETF share in Q1 2026, an estimated $125.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Osbon Capital Management's portfolio in Q1 2026, its #283 holding.
  • Osbon Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 2 quarters since.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Osbon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.